LYEL
Lyell Immunopharma Inc
NASDAQ: LYEL · HEALTHCARE · BIOTECHNOLOGY
$11.31
+3.43% today
Updated 2026-10-29
Market cap
$230.10M
P/E ratio
—
P/S ratio
8,522.34x
EPS (TTM)
$-12.86
Dividend yield
—
52W range
$7 – $45
Volume
0.1M
Lyell Immunopharma Inc (LYEL) Insider transactions
Net insider activity
Net buying (8,020,184 shares)
Buy transactions
57
Sell transactions
43
All transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-08-21 | SEELY, LYNN | Director, President and CEO | Sale | 9,589 | $15.54 | $149013.06 |
| 2026-08-21 | LEE, GARY K. | Chief Scientific Officer | Sale | 1,457 | $15.54 | $22641.78 |
| 2026-08-21 | HILL, STEPHEN J. | Chief Operating Officer | Sale | 989 | $15.54 | $15369.06 |
| 2026-08-10 | SEELY, LYNN | Director, President and CEO | Sale | 390 | $14.34 | $5592.60 |
| 2026-08-10 | LEE, GARY K. | Chief Scientific Officer | Sale | 131 | $14.34 | $1878.54 |
| 2026-08-10 | HILL, STEPHEN J. | Chief Operating Officer | Sale | 89 | $14.34 | $1276.26 |
| 2026-08-10 | BULIS, VERONICA SANCHEZ | VP, Corporate Controller | Sale | 621 | $14.34 | $8905.14 |
| 2026-07-27 | INNOVATIVE, CELLULAR THERAPEUTICS HOLDINGS LTD | 10% Owner | Sale | 44,000 | — | — |
| 2026-07-27 | INNOVATIVE, CELLULAR THERAPEUTICS HOLDINGS LTD | 10% Owner | Sale | 38,500 | — | — |
| 2026-07-17 | INNOVATIVE, CELLULAR THERAPEUTICS HOLDINGS LTD | 10% Owner | Sale | 10 | $13.70 | $137.00 |
| 2026-07-16 | INNOVATIVE, CELLULAR THERAPEUTICS HOLDINGS LTD | 10% Owner | Sale | 10 | $13.73 | $137.30 |
| 2026-06-29 | INNOVATIVE, CELLULAR THERAPEUTICS HOLDINGS LTD | 10% Owner | Sale | 76,000 | — | — |
| 2026-06-15 | INNOVATIVE, CELLULAR THERAPEUTICS HOLDINGS LTD | 10% Owner | Sale | 66,500 | — | — |
| 2026-06-10 | SHOOK, DAVID | Chief Medical Officer | Sale | 1,977 | $12.64 | $24989.28 |
| 2026-06-10 | RIEFLIN, WILLIAM JL | Director | Buy | 9,250 | — | — |
| 2026-06-10 | RAMACHANDRA, SUMANT | Director | Buy | 9,250 | — | — |
| 2026-06-10 | NABEL, ELIZABETH G | Director | Buy | 9,250 | — | — |
| 2026-06-10 | KLAUSNER, RICHARD | Director | Buy | 9,250 | — | — |
| 2026-06-10 | FRIEDMAN, CATHY | Director | Buy | 9,250 | — | — |
| 2026-06-10 | BRAWLEY, OTIS W | Director | Buy | 9,250 | — | — |
| 2026-06-10 | BACHLEDA, MARK | Director | Buy | 9,250 | — | — |
| 2026-05-11 | SEELY, LYNN | Director, President and CEO | Sale | 388 | $18.91 | $7337.08 |
| 2026-05-11 | LEE, GARY K. | Chief Scientific Officer | Sale | 130 | $18.92 | $2459.60 |
| 2026-05-11 | HILL, STEPHEN J. | Chief Operating Officer | Sale | 89 | $18.92 | $1683.88 |
| 2026-05-11 | BULIS, VERONICA SANCHEZ | VP, Corporate Controller | Sale | 217 | $18.91 | $4103.47 |
| 2026-03-09 | SHAH, SMITAL | Chief Fin. and Bus. Officer | Buy | 140,000 | — | — |
| 2026-03-06 | ARCH, VENTURE PARTNERS IX, LLC | 10% Owner | Buy | 488,090 | $25.61 | $12.50M |
| 2026-03-06 | ARCH, VENTURE FUND XIII, L.P. | 10% Owner | Buy | 488,090 | $25.61 | $12.50M |
| 2026-02-11 | SEELY, LYNN | Director, President and CEO | Sale | 7,455 | $23.39 | $174372.45 |
| 2026-02-11 | LEE, GARY K. | Chief Scientific Officer | Sale | 1,671 | $23.39 | $39084.69 |
| 2026-02-11 | HILL, STEPHEN J. | Chief Operating Officer | Sale | 1,236 | $23.39 | $28910.04 |
| 2026-02-10 | SHOOK, DAVID | Chief Medical Officer | Buy | 50,000 | — | — |
| 2026-02-10 | SEELY, LYNN | Director, President and CEO | Buy | 155,000 | — | — |
| 2026-02-10 | SEELY, LYNN | Director, President and CEO | Sale | 438 | $23.12 | $10126.56 |
| 2026-02-10 | MELTZ, MARK A | General Counsel | Buy | 50,000 | — | — |
| 2026-02-10 | LEE, GARY K. | Chief Scientific Officer | Buy | 50,000 | — | — |
| 2026-02-10 | LEE, GARY K. | Chief Scientific Officer | Sale | 147 | $23.12 | $3398.64 |
| 2026-02-10 | HILL, STEPHEN J. | Chief Operating Officer | Buy | 65,000 | — | — |
| 2026-02-10 | HILL, STEPHEN J. | Chief Operating Officer | Sale | 109 | $23.12 | $2520.08 |
| 2026-02-10 | BULIS, VERONICA SANCHEZ | VP, Corporate Controller | Buy | 8,750 | — | — |
| 2026-02-10 | BULIS, VERONICA SANCHEZ | VP, Corporate Controller | Sale | 254 | $23.12 | $5872.48 |
| 2026-02-09 | SEELY, LYNN | Director, President and CEO | Buy | 20,000 | — | — |
| 2026-02-09 | LEE, GARY K. | Chief Scientific Officer | Buy | 4,000 | — | — |
| 2026-02-09 | HILL, STEPHEN J. | Chief Operating Officer | Buy | 4,000 | — | — |
| 2025-12-30 | BULIS, VERONICA SANCHEZ | VP, Corporate Controller | Sale | 936 | $32.32 | $30251.52 |
| 2025-12-24 | BULIS, VERONICA SANCHEZ | VP, Corporate Controller | Sale | 1,136 | $38.67 | $43929.12 |
| 2025-11-10 | SEELY, LYNN | Director, President and CEO | Sale | 412 | $16.11 | $6637.32 |
| 2025-11-10 | LEE, GARY K. | Chief Scientific Officer | Sale | 138 | $16.16 | $2230.08 |
| 2025-11-10 | HILL, STEPHEN J. | Chief Operating Officer | Sale | 95 | $16.12 | $1531.40 |
| 2025-11-10 | BULIS, VERONICA SANCHEZ | VP, Corporate Controller | Sale | 239 | $16.10 | $3847.90 |
| 2025-10-27 | SEELY, LYNN | Director, President and CEO | Buy | 175,000 | — | — |
| 2025-10-27 | LEE, GARY K. | Chief Scientific Officer | Buy | 68,000 | — | — |
| 2025-10-27 | HILL, STEPHEN J. | Chief Operating Officer | Buy | 75,000 | — | — |
| 2025-08-21 | SEELY, LYNN | Director, President and CEO | Sale | 7,257 | $10.54 | $76517.81 |
| 2025-08-21 | NEWTON, CHARLES W. | Chief Financial Officer | Sale | 1,453 | $10.54 | $15320.43 |
| 2025-08-21 | LEE, GARY K. | Chief Scientific Officer | Sale | 1,453 | $10.54 | $15320.43 |
| 2025-08-21 | HILL, STEPHEN J. | Chief Operating Officer | Sale | 1,004 | $10.54 | $10586.18 |
| 2025-08-20 | SEELY, LYNN | Director, President and CEO | Buy | 40,000 | — | — |
| 2025-08-20 | NEWTON, CHARLES W. | Chief Financial Officer | Buy | 8,000 | — | — |
| 2025-08-20 | LEE, GARY K. | Chief Scientific Officer | Buy | 8,000 | — | — |
| 2025-08-20 | HILL, STEPHEN J. | Chief Operating Officer | Buy | 8,000 | — | — |
| 2025-08-12 | SEELY, LYNN | Director, President and CEO | Sale | 406 | $10.34 | $4197.23 |
| 2025-08-12 | NEWTON, CHARLES W. | Chief Financial Officer | Sale | 136 | $10.34 | $1405.97 |
| 2025-08-12 | LEE, GARY K. | Chief Scientific Officer | Sale | 136 | $10.34 | $1405.97 |
| 2025-08-12 | HILL, STEPHEN J. | Chief Operating Officer | Sale | 94 | $10.34 | $971.77 |
| 2025-08-11 | SEELY, LYNN | Director, President and CEO | Sale | 391 | $10.53 | $4115.67 |
| 2025-08-11 | NEWTON, CHARLES W. | Chief Financial Officer | Sale | 131 | $10.53 | $1378.91 |
| 2025-08-11 | LEE, GARY K. | Chief Scientific Officer | Sale | 131 | $10.53 | $1378.91 |
| 2025-08-11 | HILL, STEPHEN J. | Chief Operating Officer | Sale | 91 | $10.53 | $957.87 |
| 2025-06-09 | SHOOK, DAVID | Chief Medical Officer | Buy | 43,750 | — | — |
| 2025-06-09 | SHOOK, DAVID | Chief Medical Officer | Buy | 21,900 | — | — |
| 2025-06-09 | MELTZ, MARK A | General Counsel | Buy | 100,000 | — | — |
| 2025-06-09 | BACHLEDA, MARK | Director | Buy | 13,000 | — | — |
| 2025-05-15 | RIEFLIN, WILLIAM JL | Director | Buy | 130,000 | — | — |
| 2025-05-15 | RAMACHANDRA, SUMANT | Director | Buy | 130,000 | — | — |
| 2025-05-15 | NABEL, ELIZABETH G | Director | Buy | 130,000 | — | — |
| 2025-05-15 | KLAUSNER, RICHARD | Director | Buy | 130,000 | — | — |
| 2025-05-15 | FRIEDMAN, CATHY | Director | Buy | 130,000 | — | — |
| 2025-05-15 | BRAWLEY, OTIS W | Director | Buy | 130,000 | — | — |
| 2025-03-31 | BRAWLEY, OTIS W | Director | Buy | 35,640 | $0.56 | $19958.40 |
| 2025-03-21 | RAMACHANDRA, SUMANT | Director | Buy | 200,000 | $0.58 | $115220.00 |
| 2025-03-17 | NEWTON, CHARLES W. | Chief Financial Officer | Buy | 200,000 | $0.56 | $111620.00 |
| 2025-03-14 | SEELY, LYNN | Director, President and CEO | Buy | 175,000 | $0.61 | $106190.00 |
| 2025-03-14 | KLAUSNER, RICHARD | Director | Buy | 158,000 | $0.60 | $94942.20 |
| 2025-02-10 | SEELY, LYNN | Director, President and CEO | Buy | 1,350,000 | — | — |
| 2025-02-10 | SEELY, LYNN | Director, President and CEO | Buy | 168,750 | — | — |
| 2025-02-10 | SEELY, LYNN | Director, President and CEO | Buy | 337,500 | — | — |
| 2025-02-10 | NEWTON, CHARLES W. | Chief Financial Officer | Buy | 450,000 | — | — |
| 2025-02-10 | NEWTON, CHARLES W. | Chief Financial Officer | Buy | 56,250 | — | — |
| 2025-02-10 | NEWTON, CHARLES W. | Chief Financial Officer | Buy | 112,500 | — | — |
| 2025-02-10 | LEE, GARY K. | Chief Scientific Officer | Buy | 450,000 | — | — |
| 2025-02-10 | LEE, GARY K. | Chief Scientific Officer | Buy | 56,250 | — | — |
| 2025-02-10 | LEE, GARY K. | Chief Scientific Officer | Buy | 112,500 | — | — |
| 2025-02-10 | LANG, MATTHEW | Chief Business Officer | Buy | 450,000 | — | — |
| 2025-02-10 | LANG, MATTHEW | Chief Business Officer | Buy | 56,250 | — | — |
| 2025-02-10 | LANG, MATTHEW | Chief Business Officer | Buy | 112,500 | — | — |
| 2025-02-10 | HILL, STEPHEN J. | Chief Operating Officer | Buy | 450,000 | — | — |
| 2025-02-10 | HILL, STEPHEN J. | Chief Operating Officer | Buy | 56,250 | — | — |
| 2025-02-10 | HILL, STEPHEN J. | Chief Operating Officer | Buy | 112,500 | — | — |
| 2024-10-31 | RAMACHANDRA, SUMANT | Director | Buy | 260,000 | — | — |
Frequently asked questions
Are LYEL insiders buying or selling?
Over the transactions on record, LYEL insiders have been net buyers, with about $731793.46 in stock sold across 43 sales, against 7 open-market purchases.
Does insider selling at LYEL mean the stock will fall?
Not by itself. Most executive selling is pre-scheduled through 10b5-1 plans filed months in advance, and insiders sell for diversification, taxes, and liquidity far more often than out of any view on the price. Insider buying is the stronger signal, especially when several insiders buy around the same time, because there is usually only one reason to put personal cash into the stock.
Which LYEL insiders are selling the most?
Recent selling is concentrated in a few names. SEELY, LYNN accounts for the largest share on record, with about $437909.77 sold. Selling by one or two individuals matters less than broad selling across the whole leadership team, which is the pattern worth watching.